Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 Nov 2025
A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, you may be faced with multiple treatment options and asked to make a choice—surgery, radiation ...
Read Full NewsPsychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
Glofitamab Regimen Improves Survival in DLBCL
2.
Losing a reward can affect your motivation and performance.
3.
After targeted agents, a novel bispecific in EGFR-mutant lung cancer improves PFS.
4.
The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.
5.
PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.
1.
First-Line Immuno-Hematology Examinations: Essential Diagnostic Tools for Patient Care
2.
Fresh Frozen Plasma: Its Role in Treating Trauma and Bleeding Disorders
3.
The Unseen Danger of Anal Cancer: How to Protect Yourself
4.
AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined
5.
Improving TIVAP Use: Review of Standardization and Optimization Practices
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
2.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
3.
Efficient Management of First line ALK-rearranged NSCLC - Part II
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge